Can guideline-defined asthma control be achieved? The gaining optimal asthma control study

American Journal of Respiratory and Critical Care Medicine

Volumn 170, Issue 8, 2004, Pages 836-844

  Bateman, Eric D ^a   Boushey, Homer A ^b   Bousquet, Jean ^b   Busse, William W ^b   Clark, Tim J H ^b   Pauwels, Romain A ^b   Pedersen, Søren E ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b NONE

Author keywords

Antiasthmatic agents; Fluticasone propionate; Guidelines; Quality of life; Salmeterol

Indexed keywords

BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEADACHE; HEALTH STATUS; HOARSENESS; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; PAIN; PARALLEL DESIGN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SINUSITIS; THRUSH; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADRENAL CORTEX HORMONES; ADULT; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; PRACTICE GUIDELINES; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 5144221336     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200401-033OC     Document Type: Article

References (41)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: NHLBI/WHO Workshop Report. Bethesda: National Institutes of Health, National Heart, Lung and Blood Institute; 2002. Publication No. 02-3659.
2. British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2003;58:i1-i94.
3. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma: expert panel report 2. Bethesda: National Institutes of Health, National Heart, Lung and Blood Institute; 1997. Publication No. 97-4051.
4. Adams RJ, Fuhlbrigge A, Guilbert T, Lozano P, Martinez F. Inadequate use of asthma medication in the United States: results of the asthma in America national population survey. J Allergy Clin Immunol 2002;110:58-64.
5. Lai CKW, de Guia TS, Kim Y-Y, Kuo S-H, Mukhopadhyay A, Soriano JB, Trung PL, Zhong NS, Zainudin N, Zainudin BM. Asthma control in the Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific Study. J Allergy Clin Immunol 2003;111:263-268.
6. Rabe KF, Vermeire PA, Soriano J, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000;16:802-807.
7. Holt S, Kljakovic M, Reid J. Asthma morbidity, control and treatment in New Zealand: results of the Patient Outcomes Management Survey (POMS), 2001. N Z Med J 2003;116:U436.
8. Jones KG, Bell J, Fehrenbach C, Pearce L, Grimley D, McCarthy TP. Understanding patient perceptions of asthma: results of the Asthma Control and Expectations (ACE) survey. Int J Clin Pract 2002;56:89-93.
9. Bateman ED, Bousquet J, Braunstein GL. Is overall asthma control being achieved? A hypothesis-generating study. Eur Respir J 2001;17:589-595.
10. Bateman ED, Frith L, Braunstein GL. Achieving guideline-based asthma control: does the patient benefit? Eur Respir J 2002;20:588-595.
11. Global Initiative for Asthma (GINA). Pocket guide for asthma management and prevention. Bethesda: National Institutes of Health, National Heart, Lung, and Blood Institute; 1998. Publication No. 95-3659B.
12. Bateman E, Boushey B, Bousquet J, Busse W, Clark T, Pauwels R, Pedersen S. Achievement of guideline-based asthma control with salmeterol/fluticasone propionate compared with fluticasone propionate alone: results of the GOAL study [abstract]. 4th Triennial World Asthma Meeting Abstract Book, February 16-19, 2004. Bangkok, Thailand: Asthma Foundation of Thailand; 2004. p. 131.
13. Boushey H, Bateman E, Bousquet J, Busse W, Clark T, Pauwels R, Pedersen S. Achieving total control of asthma with salmeterol/fluticasone propionate versus fluticasone propionate alone: GOAL study results [abstract]. 4th Triennial World Asthma Meeting Abstract Book, February 16-19, 2004. Bangkok, Thailand: Asthma Foundation of Thailand; 2004. p. 132.
14. Pedersen S, Bateman E, Boushey H, Bousquet J, Busse W, Clark T, Pauwels R. Aiming for guideline defined total control of asthma improves one-year asthma outcomes: results of the GOAL study [abstract]. 4th Triennial World Asthma Meeting Abstract Book, February 16-19, 2004. Bangkok, Thailand: Asthma Foundation of Thailand; 2004. p. 120.
15. Busse W, Bateman E, Boushey H, Bousquet J, Clark T, Pauwels R, Pedersen S. Aiming to achieve total control with salmeterol/fluticasone propionate and fluticasone propionate alone is well tolerated: GOAL 1-year safety data [abstract]. 4th Triennial World Asthma Meeting Abstract Book, February 16-19, 2004. Bangkok, Thailand: Asthma Foundation of Thailand; 2004. p. 138.
16. Pauwels R, Bateman E, Boushey H, Bousquet J, Busse W, Clark T, Pedersen S. Addition of oral corticosteroids to combination therapy has little impact on achieving total control of asthma [abstract]. 4th Triennial World Asthma Meeting Abstract Book, February 16-19, 2004. Bangkok, Thailand: Asthma Foundation of Thailand; 2004. p. 135.
17. Busse W, Bateman E, Boushey H, Bousquet J, Clark T, Pauwels R, Pedersen S. Achieving GINA/NIH guideline-based asthma control with salmeterol/fluticasone compared with fluticasone alone: the results of the GOAL study. J Allergy Clin Immunol 2004;113(2 Suppl 1):S114.
18. Pauwels R, Bateman E, Boushey H, Bousquet J, Busse W, Clark T, Pedersen S. Can total control of asthma be achieved? The results of the GOAL study. J Allergy Clin Immunol 2004;113(2 Suppl 1):S276-S277.
19. Boushey H, Bateman E, Bousquet J, Busse W, Clark T, Pauwels R, Pedersen S. Improvements in asthma outcomes following 1 year of treatment with salmeterol/fluticasone or fluticasone alone when stepped up to achieve guideline-defined total control. J Allergy Clin Immunol 2004;113(2 Suppl 1):S114-S115.
20. Clark T, Bateman E, Boushey H, Bousquet J, Busse W, Pauwels R, Pedersen S. Salmeterol/fluticasone and fluticasone alone are well tolerated over 1 year of treatment stepped-up to achieve total control: safety results of the GOAL study. J Allergy Clin Immunol 2004:113(2 Suppl 1):S115.
21. Bousquet J, Bateman E, Boushey H, Busse W, Clark T, Pauwels R, Pedersen S. The effect of oral corticosteroids and high-dose combination therapy on achieving control of refractory asthma. J Allergy Clin Immunol 2004;113(2 Suppl 1):S113.
22. Clark T, Bateman E, Boushey H, Bousquet J, Busse W, Pauwels R, Pedersen S. Time course of achievement of individual clinical goals of asthma treatment: the results of the GOAL study [abstract]. Am J Respir Crit Care Med 2004;169:A318.
23. Pauwels R, Bateman E, Boushey H, Bousquet J, Busse W, Clark T, Pedersen S. Aiming for total control of asthma reduces the risk of exacerbations: a comparison of salmeterol/fluticasone propionate vs fluticasone propionate alone [abstract]. Am J Respir Crit Care Med 2004;169:A87.
24. Bateman E, Boushey H, Bousquet J, Busse W, Clark T, Pauwels R, Pedersen S. Achieving and maintaining guideline defined asthma control with salmeterol/fluticasone propionate versus fluticasone propionate alone: the results of the GOAL study [abstract]. Am J Respir Crit Care Med 2004;169:A87.
25. Bateman E, Pauwels R, Boushey H, Bousquet J, Busse W, Clark T, Pedersen S. Aiming for total control of asthma significantly improves asthma-related quality of life: salmeterol/fluticasone propionate versus fluticasone propionate alone. Am J Respir Crit Care Med 2004;169:A87.
26. Clark TJH, Bateman ED, Boushey H, Bousquet J, Busse W, Pauwels R, Pedersen S. Aiming for total control of asthma in ICS-free patients improves traditional outcomes: results of the Gaining Optimal Asthma controL (GOAL) study [abstract]. 23rd Meeting of the European Academy of Allergology and Clinical Immunology Meeting, June 12-16, 2004. Amsterdam, The Netherlands: 204. p. 669.
27. Pedersen SE, Bateman ED, Boushey H, Bousquet J, Busse W, Clark T, Pauwels R. Aiming for total control of asthma in patients taking inhaled corticosteroids improves traditional outcomes: results of the Gaining Optimal Asthma controL (GOAL) study [abstract]. 23rd European Academy of Allergology and Clinical Immunology Meeting Abstract Book, June 12-16, 2004. Amsterdam, The Netherlands: 204. p. 670.
28. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47:76-83.
29. Ward C, Pais M, Bish R, Reid D, Feltis B, Johns D, Walters EH. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002;57:309-316.
30. Reddel HK, Jenkins CR, Marks GB, Ware SI, Xuan W, Salome CM, Badcock CA, Woolcock AJ. Optimal asthma control, starting with high doses of inhaled budesonide. Eur Respir J 2000;16:226-235.
31. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003;168:1308-1311.
32. Pedersen B, Dahl R, Karlstrom R, Peterson CG, Venge P. Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide: the impact of smoking. Am J Respir Crit Care Med 1996;153:1519-1529.
33. Kavuru M, Melamed J, Gross G, LaForce C, House K, Prillaman B, Baitinger L, Woodring A, Shah T. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000;150:1108-1116.
34. Shapiro G, Lumry W, Wolfe J, Given J, White MV, Woodring A, Baitinger L, House K, Prillaman B, Shah T. Combined salmeterol 50mcg and fluticasone propionate 250 mcg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000;161:527-534.
35. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392-1397.
36. Chapman KR, Ernst P, Grenville A, Dewland P, Zimmerman S. Control of asthma in Canada: failure to achieve guideline targets. Can Respir J 2001;8:35A-40A.
37. Aubier M, Pieters WR, Schlösser NJJ, Steinmetz K-O. Salmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus inhaler (Seretide/Advair) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999;93:876-884.
38. Li JTC, Ford LB, Chervinsky P, Weisberg SC, Kellerman DJ, Faulkner KG, Herje NE, Hamedani A, Harding SM, Shah T. Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma. J Allergy Clin Immunol 1999;103:1062-1068.
39. Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003;112:S1-S40.
40. European Community for Coal and Steel. Standardisation of lung function tests as contained in the report of the working party of the European Community for Steel and Coal. Bull Eur Physiopathol Respir 1983;19:1-95.
41. Polgar G, Promadhat V. Pulmonary function testing in children: techniques and standards. Philadelphia: WB Saunders Company; 1971. p. 254.